peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
So pressure increases with depth below the surface of a liquid, as z denotes the distance from the surface of the liquid into it. Any object with a non-zero vertical depth will have different pressures on its top and bottom, with the pressure on the bottom being greater. This difference in pressure causes the upward buoyancy force. The buoyancy force exerted on a body can now be calculated easily, since the internal pressure of the fluid is known. The force exerted on the body can be calculated by integrating the stress tensor over the surface of the body which is in contact with the fluid:
== Inspiration == Marley long considered insects the "parasites of nature" and his phobia was most triggered by insect legs. To cope with an insect phobia while traveling as a model to exotic places (like South Africa, Borneo, China, and Peru), he collected bugs for exposure therapy. Marley reflected on the benefits he's gained from interacting with the natural world, and chose to share this realization with others as he noticed bugs as a design medium. In 1998, Marley started to arrange his bug collection using a design and beauty perspective after visiting a mansion in South Africa with nature integrated throughout it. Marley's fiancé convinced him to take early works to boutiques in Beverly Hills, where eight out of initial ten stores he approached wanted to sell his works.
== Signs and symptoms == Obesity is the chief symptom of HAIR-AN. In the majority of young women affected by HAIR-AN, hyperandrogenism leads to oily skin, acne, hirsutism, menstrual irregularities and, in some cases, androgenic alopecia, clitoromegaly, changes in muscle mass and deepening of the voice. Insulin resistance can be accompanied by normal or elevated levels of glucose. Symptoms of diabetes such as polydipsia, polyuria and weight loss may sometimes be present.
Sources: en.wikipedia.org
The content of a collective agreement must include terms for an expiry date no longer than 4 years (even if the parties want an ongoing agreement), a dispute resolution clause, a term for employees to make "individual flexibility agreements" (so long as employees are "better off overall"), and a term on consultation on any "major workplace changes" that could impact employees or change hours of work. To assist, the Fair Work Regulations 2009 Schedule 2.3 prescribes a model consultation term. Under section 172, other negotiated content can be anything "pertaining to the relationship between an employer" and "employees", or unions, payroll deductions from wages for union membership dues, and how the agreement will operate. Several court decisions have unduly limited what counts as pertaining to the employment relationship, including not regulating trading hours as opposed to working time, how to deal with surpluses in a defined benefit superannuation fund, whether money was transferred to a union-controlled super-fund, and constraints on employing contract labour as opposed to equal treatment. Even more, the law restricts agreements on union rights of entry, varying restrictions on strike action, and terms requiring employers pay bargaining service fees for non-union members. Once made, an agreement covers all employees it is expressed to, and the agreement is legally binding with civil remedies for breach, with the right of the employer, any employee, and the union having standing to sue in federal court.
== Further reading == Maheshwari, Saurabh; Ingole, Dilip; Chatterjee, Samar; Rajesh, Uddandam; Anand, Varun (2021). "A case report of achondrogenesis type II (Langer-Saldino achondrogenesis)". Egyptian Journal of Radiology and Nuclear Medicine. 52 (1) 113. doi:10.1186/s43055-021-00479-0. ISSN 2090-4762. Kobayashi, Yukari; Ito, Yuki; Taniguchi, Kosuke; Harada, Kana; Yamamura, Michihiro; Sato, Taisuke; Takahashi, Ken; Kawame, Hiroshi; Hata, Kenichiro; Samura, Osamu; Okamoto, Aikou (2022-11-15). "Novel missense COL2A1 variant in a fetus with achondrogenesis type II". Human Genome Variation. 9 (1). Springer Science and Business Media LLC: 40. doi:10.1038/s41439-022-00218-5. ISSN 2054-345X. PMC 9663423. PMID 36376277.
In pharmacokinetics, the effective half-life is the rate of accumulation or elimination of a biochemical or pharmacological substance in an organism; it is the analogue of biological half-life when the kinetics are governed by multiple independent mechanisms. This is seen when there are multiple mechanisms of elimination, or when a drug occupies multiple pharmacological compartments. It reflects the cumulative effect of the individual half-lives, as observed by the changes in the actual serum concentration of a drug under a given dosing regimen. The complexity of biological systems means that most pharmacological substances do not have a single mechanism of elimination, and hence the observed or effective half-life does not reflect that of a single process, but rather the summation of multiple independent processes.
Sources: en.wikipedia.org
Bullae (blisters) Crepitus (palpable gas in tissues) Reduced or absent sensation over the skin of the affected area Ecchymosis (bruising) that progresses to skin necrosis. This is because the skin changes color from red to purple and black due to clotting blood vessels Rapid progression to shock despite antibiotic therapy is another indication of necrotizing fasciitis. However, those who are immunocompromised may not show typical symptoms. This includes but is not limited to patients with:
In 1944, Jones became the first Black-American to become a member of the American Society of Refrigeration Engineers. 1953 Merit Award, Phyllis Wheatley Auxiliary (Phillis Wheatley Club of Cleveland, Ohio), "for outstanding achievements which serve as an inspiration to youth." In 1977, he was posthumously inducted into the Minnesota Inventors Hall of Fame. In 1991, the National Medal of Technology was awarded to Joseph A. Numero and Frederick M. Jones. President George Bush presented the awards posthumously to their widows at a ceremony in the White House Rose Garden. Jones was the first Black American to receive the award. In 1996, the Thermo King Model 'C' refrigeration unit, the world's first front-mount refrigeration unit for mobile trucks, was designated an International Mechanical Engineering Landmark by the American Society of Mechanical Engineers. Jones designed and built the prototype from junkyard salvage. The challenges were to build a structural frame and refrigerant tubing connections that would withstand the constant pounding of road vibrations. In 2007, Jones was inducted into the National Inventors Hall of Fame, which honored him as a "Visionary Veteran." In the March 2009 issue of Heavy Duty Truck magazine, editor Tom Berg dubbed Jones "The King of Cool", and wrote that his "technological breakthrough redefined the global marketplace, with cultural reverberations felt from the world's largest cities to its most isolated villages." In 2015, Jones' achievements were recognized by the creators of a Black heritage-themed playground located in Minneapolis.
=== Environment and Storage === Waterlogged wood should be in the environment that it is found in (and kept wet) until a stable treatment proposal in conversation with a professional conservator is decided. To limit mold growth, waterlogged wood should be stored with proper relative humidity and temperature that does not encourage mold. Waterlogged wood will retain its structure as long as it is wet.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.